10 Jul Colin R. Dormuth
Posted at 11:11h
in
Bio
Dr. Colin Dormuth joined the Faculty of Medicine at the University of British Columbia in 2007. He is currently an Associate Professor in the Department of Anesthesiology, Pharmacology & Therapeutics and Co-Director of the Therapeutics Initiative at UBC. Previously, he served as Chair for the Pharmacoepidemiology Group at the Therapeutics Initiative (2006 to 2019). Dr. Dormuth has also been co-principal investigator for the British Columbia site of the Canadian Network for Observational Drug Effect Studies (DSEN-CNODES) since 2011. Within CNODES, he has participated as the BC Site Liason for multiple studies, served as Project Lead on the CNODES Training Team, and has been an active participant in the CNODES Methods Team.
Dr. Dormuth has over 20 years of experience using administrative health care databases to evaluate drug safety, pharmaceutical policy changes and physician prescribing behaviour. He has training in epidemiology, economic theory, applied econometrics, health services outcome research, and biostatistics. Dr. Dormuth holds Sc.D. and S.M. degrees in epidemiology from Harvard University, an M.A. in economics from the University of Victoria, and a B.A. in economics from the University of Manitoba.
As Principal Investigator or Co-Principal Investigator, Dr. Dormuth has been awarded over $47 million in research funding from the Canadian Institutes for Health Research (CIHR), of which more than $40 million has been awarded since 2011, including the Canadian Network for Observational Drug Effect Studies (CNODES).
CNODES Projects
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Site Investigator, MarketScanAssociation between incretin-based drugs and the risk of acute pancreatitis
Site Investigator, MarketScanVentricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson’s Disease
Site Investigator, British ColumbiaA multicenter observational study of incretin-based drugs and heart failure
Site Investigator, MarketScanSerotonin-norepinephrine reuptake inhibitors and the risk of AKI: A cohort study of eight administrative databases and meta-analysis
Site Investigator, MarketScanHigher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases
Project LeadHigher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases
Methods LeadHigher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases
Site Investigator, MarketScanProton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
Site Investigator, MarketScanUse of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Project LeadUse of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Site Investigator, British Columbia- Site Investigator, British Columbia
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
Site Investigator, MarketScanOccurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
Site Investigator, British ColumbiaImpact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
Project LeadComparative safety of direct oral anticoagulants and warfarin in patients with venous thromboembolism: a multicenter observational study of administrative databases
Site Investigator, MarketScanComparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort
Project Co-LeadComparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort
Site Investigator, British ColumbiaComparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort
Site Investigator, MarketScanUtilization and adverse outcomes of fluconazole during pregnancy
Project Co-LeadUtilization and adverse outcomes of fluconazole during pregnancy
Site Investigator, British ColumbiaMajor bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies
Site Investigator, British ColumbiaNetwork meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities
Collaborator, British ColumbiaLikelihood ratio meta-analysis: New motivation and approach for an old method
Project Lead, British ColumbiaHead to head comparison of the propensity score and the high-dimensional propensity score matching methods
Collaborator, British ColumbiaObservational studies of drug safety in multi-database studies: Methodological challenges and opportunities
Collaborator, British ColumbiaCNODES simulated data platform
CollaboratorAddressing confounding through extreme cohort restriction in large datasets: CNODES analysis of PPIs and pneumonia
CollaboratorSafety of bowel cleansers when combined with bisacodyl stimulant laxative
Site Investigator, MarketScanSodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Site Investigator, British ColumbiaSodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study
Site Investigator, British ColumbiaSodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study
Site Investigator, British ColumbiaSodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study
Site Investigator, British ColumbiaCharacteristics of new users of newer antidiabetic drugs in Canada and the United Kingdom
Site Investigator, British ColumbiaExtreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research
Collaborator, British ColumbiaMultiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example
Collaborator, British Columbia- Site Investigator, British Columbia
Patterns of steroid utilization in COVID-19 patients
Site Investigator, British ColumbiaRisk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Co-Site Investigator, British ColumbiaValidity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study
Site Investigator, British ColumbiaChanges in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
Site Investigator, British ColumbiaThe use of atypical antipsychotics and the risk of breast cancer
Site Investigator, British ColumbiaThe use of atypical antipsychotics and the risk of breast cancer
Site Investigator, British ColumbiaUse of proton pump inhibitors and development of acute myocardial infarction
Site Investigator, British ColumbiaProton pump inhibitors and the risk of Clostridium difficile infection
Site Investigator, British ColumbiaUtilization and adverse outcomes of fluconazole during pregnancy
Site Investigator, MarketScan